Loading...

DYN DYNE THERAPEUTICS INC US FDA Inspections 8-K Filing

DYN

DYN

DYNE THERAPEUTICS INC

(DYN)

2025 8-K

Financial Results Update

Financial Results Announced

Financial Update

Director Appointment

Stock Offering News

Loan Agreement Update

Positive Trial Results

Financial Results Announced

Board Appointment

Product Expansion

Financial Statements

Equity Offerings

Debt-Equity Swaps

Accelerated Approval Pathway

Financial Statements

Management Change

Financial Results

Financial Update

Financial Results

Leadership Changes

Financial Results

Annual Meeting of Stockholders

Public Offering

Clinical Trial Results

Financial Results Announcement

Appointment of President an...

Financial Results Announcement

Public Offering

Suspension of Prospectus

Clinical Trial Results

Financial Results Announcement

Financial Results Announcement

Departure of Directors

Financial Results Announcement

Regulation FD Disclosure

Financial Results Announcement

External Links:

On December 8, 2025, Dyne Therapeutics reported positive results from their DELIVER trial for the drug zeleciment rostudirsen in treating Duchenne muscular dystrophy, showing a significant increase in muscle dystrophin expression and improving several functional endpoints compared to placebo.

AI Assistant

DYNE THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.